1887

Abstract

Summary

An experimental septicaemia-peritonitis model was adapted to immunosuppressed mice. The mice were made neutropenic by a sublethal dose of cyclophosphamide, which resulted in a 100-fold increase in their susceptibility to intraperitoneal injection of . O18: K1. A lethal infection could be prevented by passive immunisation with anti-K1 capsular or anti-O18 LPS antibodies but not with anti-J5 bacterial antibodies. The anti-K1 and anti-O18 antisera were able to increase the LD50 of the . challenge by factors of 50 and 5, respectively. The role of nonspecific, lipopolysaccharide (LPS)-mediated resistance to infection was also investigated in this model, in which only long-living phagocytic cells such as macrophages are believed to be functional. Pretreatment of mice with LPS was shown to prevent growth of the bacterial challenge in the peritoneal cavity and blood and to result in a five-fold increase in the LD50 of the challenge strain. These findings suggest an important role for macrophages as effector cells in defence against . infection.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/00222615-25-1-33
1988-01-01
2022-05-29
Loading full text...

Full text loading...

/deliver/fulltext/jmm/25/1/medmicro-25-1-33.html?itemId=/content/journal/jmm/10.1099/00222615-25-1-33&mimeType=html&fmt=ahah

References

  1. Abernathy R S. 1957; Homologous and heterologous resistance in mice given bacterial endotoxins. Journal of Immunology 78:387–394
    [Google Scholar]
  2. Bortolussi R, Ferrieri P. 1980; Protection against Escherichia coli K1 infection in newborn rats by antibody to K1 capsular polysaccharide antigen. Infection and Immunity 28:111–117
    [Google Scholar]
  3. Buhles W C, Shifrine M. 1977; Adjuvant protection against bacterial infection in granulocytopenic mice. Journal of Infectious Diseases 136:90–95
    [Google Scholar]
  4. Cross A S, Zollinger W, Mandrell R, Gemski P, Sadoff J. 1983; Evaluation of immunotherapeutic approaches for the potential treatment of infections caused by K1-positive Escherichia coli . Journal of Infectious Diseases 147:68–76
    [Google Scholar]
  5. Elbein A D, Heath E C. 1965; The biosynthesis of cell wall lipopolysaccaride in Escherichia coli. I. The biochemical properties of a uridine diphosphate galactose-4-epimerase-less mutant. Journal of Biological Chemistry 240:1919–1925
    [Google Scholar]
  6. Galanos C, Lüderitz O, Westphal O. 1969; A new method for the extraction of R lipopolysaccharides. European Journal of Biochemistry 9:245–249
    [Google Scholar]
  7. Galelli A, Parant M, Chedid L. 1977; Role of radiosensitive and radioresistant cells in nonspecific resistance to infection of LPS-treated mice. Journal of the Reticuloendothelial Society 21:109–118
    [Google Scholar]
  8. Harvath L, Andersen B R. 1976; Evaluation of type-specific and non-type-specific Pseudomonas vaccine for treatment of Pseudomonas sepsis during granulocytopenia. Infection and Immunity 13:1139–1143
    [Google Scholar]
  9. Hunninghake G W, Fauci A S. 1976; Divergent effects of cyclophosphamide administration on mononuclear killer cells: quantitative depletion of cell numbers versus qualitative suppression of functional capabilities. Journal of Immunology 117:337–342
    [Google Scholar]
  10. Kaufman B M, Cross A S, Futrovsky S L, Sidberry H F, Sadoff J C. 1986; Monoclonal antibodies reactive with K1-encapsulated Escherichia coli lipopolysaccharide are op-sonic and protect mice against lethal challenge. Infection and Immunity 52:617–619
    [Google Scholar]
  11. Kim K S, Kang J H, Cross A S. 1986; The role of capsular antigens in serum resistance and in vivo virulence of Escherichia coli . FEMS Microbiology Letters 35:275–278
    [Google Scholar]
  12. Landy M. 1956; Increase in resistance following administration of bacterial lipopolysaccharides. Annals of the New York Academy of Sciences 66:292–303
    [Google Scholar]
  13. Lumish R M, Norden C W. 1976; Therapy of neutropenic rats infected with Pseudomonas aeruginosa . Journal of Infectious Diseases 133:538–547
    [Google Scholar]
  14. Miller J H. 1972; Experiments in molecular genetics. Cold Spring Harbor Laboratory; New York:
    [Google Scholar]
  15. Nowicki B, Vuopio-Varkila J, Viljanen P, Korhonen T K, Mäkelä P H. 1986; Fimbrial phase variation and systemic E coli infection studies in the mouse peritonitis model. Microbial Pathogenesis 1:335–347
    [Google Scholar]
  16. Petursson S R, Chervenick P A. 1982; Megakaryocytopoiesis and granulopoiesis following cyclophosphamide. Journal of Laboratory and Clinical Medicine 100:682–694
    [Google Scholar]
  17. Pierson C L, Johnson A G, Feller I. 1976; Effect of cyclophosphamide on the immune response to Pseudomonas aeruginosa in mice. Infection and Immunity 14:168–177
    [Google Scholar]
  18. Pluschke G, Achtman M. 1985; Antibodies to O-antigen of lipopolysaccharide are protective against neonatal infection with Escherichia coli K1. Infection and Immunity 49:365–370
    [Google Scholar]
  19. Reed L J, Muench H. 1938; A simple method of estimating fifty per cent end-points. American Journal of Hygiene 27:493–497
    [Google Scholar]
  20. Saxén H, Mäkelä O. 1982; The protective capacity of immune sera in experimental mouse salmonellosis is mainly due to IgM antibodies. Immunology Letters 5:267–272
    [Google Scholar]
  21. Swinscow T D V. 1978; Statistics at square one. , 4. British Medical Association; London:54–57
    [Google Scholar]
  22. Tatsukawa K, Mitsuyama M, Takeya K, Nomoto K. 1979; Differing contribution of polymorphonuclear cells and macrophages to protection of mice against Listeria mono-cytogenes and Pseudomonas aeruginosa . Journal of General Microbiology 115:161–166
    [Google Scholar]
  23. Tegtmeier B R, Andersen B R. 1983; Mechanisms of lipopolysac-charide-induced protection against Pseudomonas sepsis in granulocytopenic mice. Reviews of Infectious Diseases 5:S963–S970
    [Google Scholar]
  24. Trautmann M, Müller-Leutloff Y, Hofstaetter T, Seiler F R, Hahn H. 1985; Experimental Klebsiella septicaemia in mice: treatment with specific antibodies from the rabbit alone and in combination with gentamicin. Infection 13:29–34
    [Google Scholar]
  25. Tsuru S, Nomoto K, Mitsuyama M, Zinnaka Y, Takeya K. 1981; Importance of polymorphonuclear leucocytes in protection of mice against Escherichia coli . Journal of General Microbiology 122:335–338
    [Google Scholar]
  26. Turk J L, Parker D. 1982; Effect of cyclophosphamide on immunological control mechanisms. Immunological Reviews 65:99–113
    [Google Scholar]
  27. Van der Ley P, Kuipers O, Tommassen J, Lugtenberg B. 1986; O-antigenic chains of lipopolysaccharide prevent binding of antibody molecules to an outer membrane pore protein in Enterobacteriaceae. Microbial Pathogenesis 1:43–49
    [Google Scholar]
  28. Vuopio-Varkila J, Karvonen M, Saxen H. 1988a; The protective capacity of antibodies to various outer membrane components in a systemic mouse peritonitis model caused by Escherichia coli O18:K1. Journal of Medical Microbiology. In press
    [Google Scholar]
  29. Vuopio-Varkila J, Nurminen M, Phyälä L, Mäkelä P H. 1988b; LPS-induced nonspecific resistance to systemic Escherichia coli infection in mice. Journal of Medical Microbiology. In press
    [Google Scholar]
  30. Weinstein M P, Murphy J R, Reller L B, Lichtenstein K A. 1983a; The clinical significance of positive blood cultures: a comprehensive analysis of 500 episodes of bacteremia and fungemia in adults. II. Clinical observations with special reference to factors influencing prognosis. Reviews of Infectious Diseases 5:54–70
    [Google Scholar]
  31. Weinstein M P, Reller L B, Murphy J R, Lichtenstein K A. 1983b; The clinical significance of positive blood cultures: a comprehensive analysis of 500 episodes of bacteremia and fungemia in adults. I. Laboratory and epidemiologic observations. Reviews of Infectious Diseases 5:35–53
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/00222615-25-1-33
Loading
/content/journal/jmm/10.1099/00222615-25-1-33
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error